Bio-Techne (TECH) Common Equity (2009 - 2026)

Bio-Techne's Common Equity history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 3.33% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 3.33% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 7.25% from the prior year.
• Common Equity climbed to $2.1 billion in Q1 2026 per TECH's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Common Equity topped out at $2.1 billion in Q3 2024 and bottomed at $1.7 billion in Q2 2022.
• The 5-year median for Common Equity is $2.0 billion (2023), against an average of $1.9 billion.
• Across the five-year window, Common Equity increased 15.61% in 2023 and decreased 8.08% in 2025, its largest moves.
• Year by year, Common Equity stood at $1.8 billion in 2022, then grew by 7.47% to $2.0 billion in 2023, then gained by 5.85% to $2.1 billion in 2024, then declined by 3.25% to $2.0 billion in 2025, then gained by 3.7% to $2.1 billion in 2026.
• Per Business Quant, the three latest TECH Common Equity figures stand at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025).